Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.99−0.02 (-1.00%)
Close on Nov 12, 2026Market cap $73.19MP/E –Yield –
Fortress Biotech profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Fortress Biotech's profit margin for the twelve months ending Sep 30, 2026 was 143.0%. For fiscal 2025 it was 10.8%, against -79.8% the year before. The highest annual figure on record is 10.8% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.8% | +90.5 |
| FY2024 | Dec 31, 2024 | -79.8% | −8.0 |
| FY2023 | Dec 31, 2023 | -71.7% | +42.6 |
| FY2022 | Dec 31, 2022 | -114.3% | −20.2 |
| FY2021 | Dec 31, 2021 | -94.1% | +8.0 |
| FY2020 | Dec 31, 2020 | -102.0% | +7.1 |
| FY2019 | Dec 31, 2019 | -109.1% | +203.9 |
| FY2018 | Dec 31, 2018 | -313.0% | +74.8 |
| FY2017 | Dec 31, 2017 | -387.8% | −53.5 |
| FY2016 | Dec 31, 2016 | -334.3% | +5277.3 |
| FY2015 | Dec 31, 2015 | -5611.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -30.5% | −63.7 |
| Q2 FY2026 | Jun 30, 2026 | -2.5% | −96.9 |
| Q1 FY2026 | Mar 31, 2026 | 688.2% | +768.8 |
| Q4 FY2025 | Dec 31, 2025 | -24.5% | +20.3 |
| Q3 FY2025 | Sep 30, 2025 | 33.2% | +121.1 |
| Q2 FY2025 | Jun 30, 2025 | 94.4% | +167.8 |
| Q1 FY2025 | Mar 31, 2025 | -80.6% | +37.8 |
| Q4 FY2024 | Dec 31, 2024 | -44.7% | +1.8 |
| Q3 FY2024 | Sep 30, 2024 | -88.0% | −73.4 |
| Q2 FY2024 | Jun 30, 2024 | -73.5% | +69.0 |
| Q1 FY2024 | Mar 31, 2024 | -118.3% | +55.0 |
| Q4 FY2023 | Dec 31, 2023 | -46.5% | +117.8 |
| Q3 FY2023 | Sep 30, 2023 | -14.5% | +121.7 |
| Q2 FY2023 | Jun 30, 2023 | -142.5% | −29.4 |
| Q1 FY2023 | Mar 31, 2023 | -173.3% | −107.4 |
| Q4 FY2022 | Dec 31, 2022 | -164.3% | +8.4 |
| Q3 FY2022 | Sep 30, 2022 | -136.2% | −37.6 |
| Q2 FY2022 | Jun 30, 2022 | -113.1% | −93.3 |
| Q1 FY2022 | Mar 31, 2022 | -65.9% | +10.3 |
| Q4 FY2021 | Dec 31, 2021 | -172.7% | −134.2 |
| Q3 FY2021 | Sep 30, 2021 | -98.6% | +65.5 |
| Q2 FY2021 | Jun 30, 2021 | -19.8% | +121.0 |
| Q1 FY2021 | Mar 31, 2021 | -76.1% | +19.6 |
| Q4 FY2020 | Dec 31, 2020 | -38.5% | +100.7 |
| Q3 FY2020 | Sep 30, 2020 | -164.1% | −33.5 |
| Q2 FY2020 | Jun 30, 2020 | -140.8% | +0.8 |
| Q1 FY2020 | Mar 31, 2020 | -95.8% | −117.2 |
| Q4 FY2019 | Dec 31, 2019 | -139.2% | +137.5 |
| Q3 FY2019 | Sep 30, 2019 | -130.6% | +191.0 |
| Q2 FY2019 | Jun 30, 2019 | -141.6% | +175.5 |
| Q1 FY2019 | Mar 31, 2019 | 21.5% | +377.5 |
| Q4 FY2018 | Dec 31, 2018 | -276.7% | −138.7 |
| Q3 FY2018 | Sep 30, 2018 | -321.6% | +754.4 |
| Q2 FY2018 | Jun 30, 2018 | -317.1% | +77.2 |
| Q1 FY2018 | Mar 31, 2018 | -356.1% | +75.3 |
| Q4 FY2017 | Dec 31, 2017 | -138.0% | −17.0 |
| Q3 FY2017 | Sep 30, 2017 | -1076.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -394.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -431.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -121.0% | – |
See a number that looks wrong?